Irisin alleviated the reproductive endocrinal disorders of PCOS mice accompanied by changes in gut microbiota and metabolomic characteristics
From BugSigDB
Jump to:navigation, search
Study information
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
study design
Citation
PMID PubMed identifier for scientific articles.
DOI Digital object identifier for electronic documents.
URI Uniform resource identifier for web resources.
Authors
Yang M, Deng H, Zhou S, Lu D, Shen X, Huang L, Chen Y, Xu L
Journal
Frontiers in microbiology
Year
2024
Keywords:
fecal metabolomics, folliculogenesis, gut microbiota, irisin, polycystic ovary syndrome
INTRODUCTION: Folliculogenesis and oligo/anovulation are common pathophysiological characteristics in polycystic ovary syndrome (PCOS) patients, and it is also accompanied by gut microbiota dysbiosis. It is known that physical activity has beneficial effects on improving metabolism and promoting ovulation and menstrual cycle disorder in PCOS patients, and it can also modulate the gastrointestinal microbiota in human beings. However, the mechanism remains vague. Irisin, a novel myokine, plays a positive role in the mediating effects of physical activity. METHODS: Mice were randomly divided into the control group, PCOS group and PCOS+irisin group. PCOS model was induced by dehydroepiandrosterone (DHEA) and high-fat diet (HFD). The PCOS+irisin group was given irisin 400μg/kg intraperitoneal injection every other day for 21 days. The serum sex hormones were measured by radioimmunoassay. Hematoxylin and Eosin (H&E) Staining and immunohistochemistry (IHC) were conducted on ovarian tissue. The feces microbiota and metabolomic characteristics were collected by 16S rRNA gene sequencing and liquid chromatography-mass spectrometry (LC-MS). RESULTS: In this study, we demonstrated that irisin supplementation alleviated reproductive endocrine disorders of PCOS mice, including estrous cycle disturbance, ovarian polycystic degeneration, and hyperandrogenemia. Irisin also improved the PCOS follicles dysplasia and ovulation disorders, while it had no significant effect on the quality of oocytes. Moreover, irisin could mitigate the decreased bacteria of Odoribacter and the increased bacteria of Eisenbergiella and Dubosiella in PCOS mice model. Moreover, irisin could alleviate the increased fecal metabolites: Methallenestril and PS (22:5(4Z,7Z,10Z,13Z,16Z)/ LTE4). CONCLUSION: These results suggest that irisin may alleviate the status of PCOS mice model by modulating androgen-induced gut microbiota dysbiosis and fecal metabolites. Hence, our study provided evidence that irisin may be considered as a promising strategy for the treatment of PCOS.
Experiment 1
Subjects
- Location of subjects
- China
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Mus musculus
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Polycystic ovary syndrome & Polycystic ovary syndrome+Irisin (PCOS & PCOS+Irisin)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Vehicle
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Animals in this group were injected daily with corn oil subcutaneously along with a control diet.
- Group 0 sample size Number of subjects in the control (unexposed) group
- 14
- Group 1 sample size Number of subjects in the case (exposed) group
- 5
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- Not specified
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- PacBio RS
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- LEfSe
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- No
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- 2
Signature 1
Source: Figure 5C
Description: Cladogram and bar plot of the LEfSe analysis showing the most characteristic taxa in each group of mice (taxa with LDA score > 2.0).
Abundance in Group 1: increased abundance in Vehicle
| NCBI | Quality Control | Links |
|---|---|---|
| Eubacterium coprostanoligenes | ||
| Peptostreptococcaceae | ||
| Romboutsia ilealis | ||
| Romboutsia |
Revision editor(s): Victoria
Experiment 2
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Vehicle & Polycystic ovary syndrome+Irisin (PCOS+Irisin)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome (PCOS)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Animals in this group were subcutaneously injected daily with DHEA (D4000; Sigma–Aldrich; 6 mg per 100 g, dissolved in corn oil) and were fed with a high-fat diet (HFD).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 13
- Group 1 sample size Number of subjects in the case (exposed) group
- 6
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5C
Description: Cladogram and bar plot of the LEfSe analysis showing the most characteristic taxa in each group of mice (taxa with LDA score > 2.0).
Abundance in Group 1: increased abundance in Polycystic ovary syndrome (PCOS)
| NCBI | Quality Control | Links |
|---|---|---|
| Blautia producta | ||
| Desulfovibrio |
Revision editor(s): Victoria
Experiment 3
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Treatment outcome measurement Treatment outcome measurement,treatment outcome measurement
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Vehicle & Polycystic ovary syndrome (PCOS)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome+Irisin (PCOS+Irisin)
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Animals in this group were injected daily with DHEA subcutaneously, 400 μg/kg r-irisin intraperitoneally every other day, and were fed with a high-fat diet (HFD).
- Group 0 sample size Number of subjects in the control (unexposed) group
- 11
- Group 1 sample size Number of subjects in the case (exposed) group
- 8
Lab analysis
Statistical Analysis
Signature 1
Source: Figure 5C
Description: Cladogram and bar plot of the LEfSe analysis showing the most characteristic taxa in each group of mice (taxa with LDA score > 2.0).
Abundance in Group 1: increased abundance in Polycystic ovary syndrome+Irisin (PCOS+Irisin)
| NCBI | Quality Control | Links |
|---|---|---|
| Gammaproteobacteria | ||
| Lachnospiraceae bacterium 10-1 | ||
| Limosilactobacillus reuteri | ||
| Lachnospiraceae bacterium NK4A136 |
Revision editor(s): Victoria
Experiment 4
Differences from previous experiment shown
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Polycystic ovary syndrome Cystic disease of ovaries,hyperandrogenemia,Multicystic ovaries,multicystic ovaries,Ovarian Degeneration, Sclerocystic,Ovarian Syndrome, Polycystic,Ovarian Syndromes, Polycystic,Ovaries, Sclerocystic,Ovary Syndrome, Polycystic,Ovary, Sclerocystic,PCO - Polycystic ovaries,Pco1,PCOD - Polycystic ovarian disease,PCOS,Pcos,PCOS - Polycystic ovarian syndrome,PCOS1,Polycystic ovarian disease,polycystic ovarian disease,Polycystic ovarian syndrome,Polycystic ovaries,polycystic ovaries,Polycystic ovaries (disorder),polycystic ovary,polycystic ovary syndrome,polycystic ovary syndrome 1,Sclerocystic Ovarian Degeneration,Sclerocystic Ovaries,Sclerocystic Ovary,Sclerocystic Ovary Syndrome,Stein Leventhal Syndrome,Stein-Leventhal synd.,Stein-Leventhal Syndrome,Stein-Leventhal syndrome,Syndrome, Polycystic Ovary,Syndrome, Stein-Leventhal,Polycystic ovary syndrome
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Vehicle
- Group 0 sample size Number of subjects in the control (unexposed) group
- 5
Lab analysis
Statistical Analysis
- Statistical test
- ANOVA
- LDA Score above Threshold for the linear discriminant analysis (LDA) score for studies using the popular LEfSe tool
- Not specified
Alpha Diversity
- Richness Number of species
- unchanged
Signature 1
Source: Figure 5D
Description: The variance analysis of abundant taxa at the genus level among the three groups of mice.
Abundance in Group 1: increased abundance in Polycystic ovary syndrome+Irisin (PCOS+Irisin)
| NCBI | Quality Control | Links |
|---|---|---|
| Christensenella |
Revision editor(s): Victoria
Experiment 5
Differences from previous experiment shown
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Polycystic ovary syndrome (PCOS)
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Polycystic ovary syndrome (PCOS) Polycystic ovary syndrome+Irisin (PCOS+Irisin)
- Group 0 sample size Number of subjects in the control (unexposed) group
- 6
Lab analysis
Statistical Analysis
Alpha Diversity
- Richness Number of species
- unchanged
Signature 1
Source: Figure 5D
Description: The variance analysis of abundant taxa at the genus level among three groups of mice.
Abundance in Group 1: increased abundance in Polycystic ovary syndrome (PCOS) Polycystic ovary syndrome+Irisin (PCOS+Irisin)
| NCBI | Quality Control | Links |
|---|---|---|
| Christensenella |
Revision editor(s): Victoria
Retrieved from "https://bugsigdb.org/w/index.php?title=38846566&oldid=207628"
